(1-phenyl-1H-pyrazol-5-yl)boronic acid → 6-(2-Phenyl-2H-pyrazol-3-yl)-1-p-tolyl-1H-benzoimidazole
반응식
Br[C:2]1[CH:3]=[CH:4][C:5]2[N:9]=[CH:8][N:7]([C:10]3[CH:15]=[CH:14][C:13]([CH3:16])=[CH:12][CH:11]=3)[C:6]=2[CH:17]=1.[C:18]1([N:24]2[C:28](B(O)O)=[CH:27][CH:26]=[N:25]2)[CH:23]=[CH:22][CH:21]=[CH:20][CH:19]=1>>[C:18]1([N:24]2[C:28]([C:2]3[CH:3]=[CH:4][C:5]4[N:9]=[CH:8][N:7]([C:10]5[CH:15]=[CH:14][C:13]([CH3:16])=[CH:12][CH:11]=5)[C:6]=4[CH:17]=3)=[CH:27][CH:26]=[N:25]2)[CH:19]=[CH:20][CH:21]=[CH:22][CH:23]=1참가 물질
3
실험 절차
The title compound, off-white solid (27 mg, 22%), MS (ISP) m/z=351.3 [(M+H)+], mp 146° C., was prepared in accordance with the general method of example 1 from 6-bromo-1-p-tolyl-1H-benzo[d]imidazole (intermediate F) (100 mg, 348 μmol) and commercially available 1-phenyl-1H-pyrazol-5-ylboronic acid [CAS No. 1238702-56-1] (85.1 mg, 453 μmol).
출처 및 근거
- ORD 기록
- ord-f230ab930830466aaba1124b95aa5916
- 출처 데이터셋
- uspto-grants-2016_06